A

argenx SE
D

ARGX

596.69
USD
5.40
(0.91%)
مغلق
حجم التداول
13,235
الربح لكل سهم
-0
العائد الربحي
-
P/E
-170
حجم السوق
35,679,838,136
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    ABBV
    ABBV
    -4.630
    (-2.73%)
    171.713 USD
    BMY
    BMY
    -2.270
    (-3.88%)
    56.230 USD
    GSK
    GSK
    -1.020
    (-2.97%)
    33.350 USD
    LLY
    LLY
    -40.34
    (-5.13%)
    749.9 USD
    NVS
    NVS
    -0.350
    (-0.34%)
    103.85 USD
    PFE
    PFE
    -1.225
    (-4.71%)
    25.14 USD
    REGN
    REGN
    -25.40
    (-3.25%)
    756.82 USD
    SNY
    SNY
    0.160
    (0.33%)
    47.975 USD
    المزيد
الأخبار

العنوان: argenx SE

القطاع: Healthcare
الصناعة: Biotechnology
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.